Jeff Yass’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-200,400
| Closed | -$4.3M | – | 13575 |
|
|
2026
Q1 | $4.3M | Buy |
200,400
+171,600
| +596% | +$2.42M | ﹤0.01% | 4519 |
|
|
2025
Q4 | $268K | Sell |
28,800
-14,000
| -33% | -$117K | ﹤0.01% | 10220 |
|
|
2025
Q3 | $302K | Buy |
+42,800
| New | +$294K | ﹤0.01% | 10091 |
|
|
2025
Q2 | – | Sell |
-10,100
| Closed | -$80.1K | – | 12813 |
|
|
2025
Q1 | $80.1K | Sell |
10,100
-10,300
| -50% | -$111K | ﹤0.01% | 11673 |
|
|
2024
Q4 | $258K | Buy |
20,400
+1,200
| +6% | +$16.7K | ﹤0.01% | 10147 |
|
|
2024
Q3 | $267K | Sell |
19,200
-2,800
| -13% | -$39.9K | ﹤0.01% | 9838 |
|
|
2024
Q2 | $303K | Buy |
+22,000
| New | +$322K | ﹤0.01% | 9423 |
|
|
2023
Q3 | – | Sell |
-16,900
| Closed | -$202K | – | 12153 |
|
|
2023
Q2 | $202K | Sell |
16,900
-3,300
| -16% | -$43.1K | ﹤0.01% | 10247 |
|
|
2023
Q1 | $270K | Sell |
20,200
-44,000
| -69% | -$859K | ﹤0.01% | 9952 |
|
|
2022
Q4 | $1.38M | Sell |
64,200
-7,500
| -10% | -$154K | ﹤0.01% | 5469 |
|
|
2022
Q3 | $1.44M | Buy |
71,700
+17,700
| +33% | +$376K | ﹤0.01% | 5705 |
|
|
2022
Q2 | $967K | Buy |
+54,000
| New | +$558K | ﹤0.01% | 6611 |
|
Other funds holding DAWN
Jeff Yass's DAWN Position: Q2 2026 in Review
Jeff Yass sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 473,543 shares — an estimated $10.2M sold.
Jeff Yass first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $10.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Jeff Yass reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 473,543 Day One Biopharmaceuticals shares in Q2 2026, an estimated $10.2M.
- Jeff Yass first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
- Jeff Yass's Day One Biopharmaceuticals position peaked at $10.2M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.